Clinical trial
Tipifarnib and Erlotinib Hydrochloride in Treating Patients With Advanced Solid…
NCT00085553 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00085553 |
|---|---|
| Title | Tipifarnib and Erlotinib Hydrochloride in Treating Patients With Advanced Solid Tumors |
| Official title | Phase I Trial of R115777 and OSI-774 in Patients With Advanced Solid Tumors |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Solid Neoplasm |
| Intervention type | Drug, Other |
| Interventions | Erlotinib Hydrochloride, Laboratory Biomarker Analysis, Pharmacological Study, Tipifarnib |
| Enrollment | 29 |
| Start date | May 20, 2004 |
| Primary completion | May 7, 2008 |
| Completion | May 16, 2018 |
| First posted | Jun 11, 2004 |
| Last update posted | May 18, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: